Dr. Mark Sampson, Chief Medical Officer of Shield Therapeutics (STX) , joined Vox Markets for a Q&A session.
A pharmaceutical physician, Dr. Sampson guides Shield’s development and commercialisation of their leading asset, Feraccru. Feraccru is a unique and leading oral drug for iron deficiency, a disease the WHO has called “the top nutritional disorder in the world.”
Dr. Sampson shares with us what differentiates Feraccru and how Shield Therapeutics is expanding the drug in several markets.
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
